Abstract: The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

Abstract: The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.

Abstract: The present invention relates to compositions comprising a recombinant attenuated Listeria strain expressing a truncated ActA and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant Listeria strain that expresses a fusion protein of a truncated ActA fused to an antigen.

Abstract: The present invention is directed to compositions comprising an immune checkpoint inhibitor or a T cell stimulator or a combination thereof, and a live attenuated recombinant Listeria strain comprising a fusion polypeptide comprising a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

Abstract: Disclosed herein are compositions comprising use of compositions comprising a live attenuated recombinant Listeria strain comprising a fusion protein of a truncated listeriolysin O (LLO) protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen, including a tumor-associated antigen, wherein the compositions further comprise or are co-administered with an antibody or fragment thereof. Also disclosed are combination therapies comprising use of these compositions comprising live attenuated recombinant Listeria strains, in conjunction with an antibody or fragment thereof for use in treating, protecting against, and/or inducing an immune response against a tumor, especially wherein the treating, protection against and/or inducing an immune response increases percent survival in a subject.

Abstract: Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.

Abstract: This invention provides a system of providing and a process of creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic vaccine delivery vectors comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to an subject's cancer or unhealthy tissue. The invention further provides a scalable fully enclosed single use cell growth system, wherein the entire process of manufacturing of personalized immunotherapeutic compositions, up to and including dispensing said composition into containers for patient delivery is carried out within a single enclosed fluid flow path.

Abstract: This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a different biomarker, thereby treating said disease in said subject.

Abstract: The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen.

Abstract: The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.

Abstract: The present disclosure provides methods of treating, protecting against, enhancing and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria. In other embodiments, the Listeria stimulates the STING pathway.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

Abstract: The applicator (1, 1?) of a cosmetic product (6) includes a manual gripping element (2) and an application member (3) of the product (6), and is characterized in that: a) the application member (3) includes at least one fixed element (30) and one rotating element (31), forming an application roller free to rotate about the fixed element (30) about a rotation axis (10), b) the fixed element (31) is typically fixed to the manual gripping element (2), c) the fixed element (30) and the rotating element (31) are fixed by reversible or irreversible cooperation. Advantages are easier application resulting in a different appearance.

Abstract: The applicator (1, 1?) of a cosmetic product (6) includes a manual gripping element (2) and an application member (3) of the product (6), and is characterized in that: a) the application member (3) includes at least one fixed element (30) and one rotating element (31), forming an application roller free to rotate about the fixed element (30) about a rotation axis (10), b) the fixed element (31) is typically fixed to the manual gripping element (2), c) the fixed element (30) and the rotating element (31) are fixed by reversible or irreversible cooperation. Advantages are easier application resulting in a different appearance.

Abstract: The applicator (1, 1?) of a cosmetic product (6) includes a manual gripping element (2) and an application member (3) of the product (6), and is characterized in that: a) the application member (3) includes at least one fixed element (30) and one rotating element 131) , forming an application roller free to rotate about the fixed element (30) about a rotation axis (10), b) the fixed element (31) is typically fixed to the manual gripping element (2), c) the fixed element (30) and the rotating element (31) are fixed by reversible or irreversible cooperation. Advantages are easier application resulting in a different appearance.

Abstract: Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

Abstract: The invention relates to a dispenser/applicator (100) comprising a recipient consisting of a body (105) and a distribution head (120) which is provided with at least one opening (121) and a cap (110) for blocking said distribution head by being axially sunk thereinto.

Abstract: The dispenser (1) for a product in powder form, typically a cosmetic product, includes a body (2) forming a cavity (20) intended to contain said product in powder form and fitted with an upper aperture (21), a means (4) for applying said powder, and a cap (3) intended to seal said upper aperture (21) via an engagement means (11), and is characterised in that: a) said engagement means (11) is selected in such a way that an axial and/or radial compression is exerted between said body (2) and said cap (3), and that said cavity (20) is thus typically leakproof when said dispenser (1) is closed, b) said cavity (20) includes a lower part (22) and an upper part (23) separated by a plate (5, 24) integral with said body (2) and fitted with orifices (50, 240), said lower part (22) containing said product in powder form, said plate (5, 24) allowing said product to move, via said orifices (50, 240), towards said application means (4), c) said application means (4) is a removable application means.